The Development and Evaluation of Novel Patient Educational Material for a Variant of Uncertain Significance (VUS) Result in Hereditary Cancer Genes

Author:

Cragun Deborah1,Dean Marleah23,Baker David4,Kelley Meghan5,Hooker Gillian4,Weidner Anne4ORCID,Hunt Paige1,Pal Tuya4

Affiliation:

1. College of Public Health, University of South Florida, Tampa, FL 33620, USA

2. Department of Communication, University of South Florida, Tampa, FL 33620, USA

3. Outcomes & Behavior Program, Moffitt Cancer Center, Tampa, FL 33612, USA

4. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37212, USA

5. Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA

Abstract

A Variant of Uncertain Significance (VUS) is a difference in the DNA sequence with uncertain consequences for gene function. A VUS in a hereditary cancer gene should not change medical care, yet some patients undergo medical procedures based on their VUS result, highlighting the unmet educational needs among patients and healthcare providers. To address this need, we developed, evaluated, and refined novel educational materials to explain that while VUS results do not change medical care, it remains important to share any personal or family history of cancer with family members given that their personal and family medical history can guide their cancer risk management. We began by reviewing the prior literature and transcripts from interviews with six individuals with a VUS result to identify content and design considerations to incorporate into educational materials. We then gathered feedback to improve materials via a focus group of multidisciplinary experts and multiple rounds of semi-structured interviews with individuals with a VUS result. Themes for how to improve content, visuals, and usefulness were used to refine the materials. In the final round of interviews with an additional 10 individuals with a VUS result, materials were described as relatable, useful, factual, and easy to navigate, and also increased their understanding of cancer gene VUS results.

Funder

National Institutes of Health through funding from the National Cancer Institute

Publisher

MDPI AG

Reference49 articles.

1. Lynch Syndrome: An Updated Review;Sehgal;Genes,2014

2. Apostolou, P., and Fostira, F. (2013). Hereditary Breast Cancer: The Era of New Susceptibility Genes. Biomed. Res. Int., 2013.

3. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing;Mersch;JAMA,2018

4. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology;Richards;Genet. Med.,2015

5. NCCN (2022). Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), National Comprehensive Cancer Network. Version 1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3